Enterprise Value

1.396B

Cash

907.7M

Avg Qtr Burn

-150.1M

Short % of Float

12.86%

Insider Ownership

6.77%

Institutional Own.

-

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Adagrasib (MRTX849) KRAS G12C Inhibitor Details
Cancer, Lung cancer, Solid tumor/s, Colorectal cancer , Non-small cell lung carcinoma

Approved

Quarterly sales

Phase 3

Data readout

Adagrasib (MRTX849) Details
Solid tumor/s, Colorectal cancer , Non-small cell lung carcinoma, Cancer, Lung cancer

Phase 3

Data readout

Adagrasib (MRTX849) + Pembrolizumab Details
Solid tumor/s, Non-small cell lung carcinoma, Cancer, Lung cancer

Phase 3

Data readout

MRTX1133 Details
Solid tumor/s, Cancer, Colorectal cancer , Pancreatic cancer, Lung cancer

Phase 1/2

Data readout

Phase 1/2

Data readout

Adagrasib (MRTX849) KRAS G12C Inhibitor + VS-6766 in KRASG12C-mutant Details
CRC (colorectal cancer) and NSCLC (Non-small cell lung cancer)

Phase 1/2

Initiation

Sitravatinib plus tislelizumab Details
Platinum-resistant ovarian cancer

Phase 1b

Interim update